<SEC-DOCUMENT>0000059478-21-000117.txt : 20210427
<SEC-HEADER>0000059478-21-000117.hdr.sgml : 20210427
<ACCEPTANCE-DATETIME>20210427064839
ACCESSION NUMBER:		0000059478-21-000117
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210427
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210427
DATE AS OF CHANGE:		20210427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		21855813

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20210427.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908,d:b96e54056c2040cbaacb9760d9db43e4--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:lly="http://www.lilly.com/20210427" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20210427</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF80L2ZyYWc6MDU3MjNiM2Q2OTIwNDRkZjhiNmJlZjNlYWZjOWIzNmYvdGFibGU6NWU5YzRmOTlmNGRlNGI2OTlhMmQyOTdjZTFlMDQwYWQvdGFibGVyYW5nZTo1ZTljNGY5OWY0ZGU0YjY5OWEyZDI5N2NlMWUwNDBhZF8yLTEtMS0xLTA_83e8637f-67a6-4b06-9dd8-c9e14b4d7921">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF80L2ZyYWc6MDU3MjNiM2Q2OTIwNDRkZjhiNmJlZjNlYWZjOWIzNmYvdGFibGU6NWU5YzRmOTlmNGRlNGI2OTlhMmQyOTdjZTFlMDQwYWQvdGFibGVyYW5nZTo1ZTljNGY5OWY0ZGU0YjY5OWEyZDI5N2NlMWUwNDBhZF81LTEtMS0xLTA_5f81be14-efa4-47c0-8c0f-edc8bc74da19">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20210427.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282cc034e78b44beb71f281568135298_D20210427-20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib96e54056c2040cbaacb9760d9db43e4_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA5_4541ec3f-7cef-4e09-9137-6bd981af1a29">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xNjU_39684d8c-0b8d-4a72-a4b2-bd6de63e168c">April 27, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjEw_6857c540-cd98-4b58-8e35-85b4fdf1100a">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTAtMS0xLTA_08141a1c-07d0-41c0-96da-76b191e1e647">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTItMS0xLTA_2bd8f4d0-3aab-4353-b338-30ba53910897">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTQtMS0xLTA_53ff2662-bda0-4515-811c-b92b612da502">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18wLTAtMS0xLTA_fb8a99d1-39b5-4a15-a742-83fabd24e190">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTAtMS0xLTA_aae6206c-b121-45d7-875d-f4a3b94f2842">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTEtMS0xLTA_22bfc361-2900-4d24-92b7-8d2e2f917638">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTItMS0xLTA_4ea02e57-0d02-47f6-96c0-8b31c50af898">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA2_458e8e96-7b95-4f4c-b6b5-4c3e6efbceae">317</ix:nonNumeric>) <ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA3_6ca47db7-30d0-4471-a72d-1c7ddf4087f7">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6NWZkZGFmZGIxZWViNDU2NGFlMWMxMzdiOGE0YWM4YTQvdGFibGVyYW5nZTo1ZmRkYWZkYjFlZWI0NTY0YWUxYzEzN2I4YTRhYzhhNF8wLTAtMS0xLTA_fc5229d2-acb9-49e8-b123-500816f0144e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6NDIyNWM5NzQwYzkwNGFhOGE4YzUzMzBiYzIxZWNlODgvdGFibGVyYW5nZTo0MjI1Yzk3NDBjOTA0YWE4YThjNTMzMGJjMjFlY2U4OF8wLTAtMS0xLTA_75f1c3e6-a619-4803-90df-f4d46c9d0bb6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6OTg5NzA1ZDE1YzM0NDY3YWIzZjkzMDBjNjU0MmIzZjMvdGFibGVyYW5nZTo5ODk3MDVkMTVjMzQ0NjdhYjNmOTMwMGM2NTQyYjNmM18wLTAtMS0xLTA_e968f240-41d9-4fde-9128-60225e50c5c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6YjNkMzdkNmFmNTMwNDQ2Y2IwODc4MmVmNDQ5YjczMWQvdGFibGVyYW5nZTpiM2QzN2Q2YWY1MzA0NDZjYjA4NzgyZWY0NDliNzMxZF8wLTAtMS0xLTA_9284ebff-ce51-444d-8f82-baa09f6e9d69">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTAtMS0xLTA_781e81f3-487f-4907-803d-c4b25708ad27">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTItMS0xLTA_2df1813a-0254-4e57-ac07-28f71d3607c6">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTQtMS0xLTA_a03ed442-29d7-404e-b221-f2fc55f4f2d5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTAtMS0xLTA_f21a13b9-097c-40e7-8e6c-c5d335555211">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTItMS0xLTA_53fdee60-f5b3-46e3-b90b-0d5f1ca81100">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTQtMS0xLTA_9e2b0ebb-f8d4-4369-9930-8a26d0ab0d57">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTAtMS0xLTA_046eaa84-4b6a-442e-853d-039468aaa5d6">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTItMS0xLTA_3b89d4d7-854e-48cc-bcca-63f666eacbdf">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTQtMS0xLTA_2648550d-3d5d-4603-ade2-b50e66fc2ded">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTAtMS0xLTA_a583f1aa-9aad-4a79-9303-ddab6fa171e9">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTItMS0xLTA_18c71fa0-3d2e-4d70-a9cb-56118231a2fd">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTQtMS0xLTA_be157bc7-b8d6-40a9-8df0-dd76500e9fd0">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTAtMS0xLTA_ecd6e461-5a27-4450-8b5f-854462aabe88">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTItMS0xLTA_43e7b7e8-e9ba-40f3-9d81-49b7609b32c3">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTQtMS0xLTA_adf41714-1cdf-4a37-b670-3d1b16032cda">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTAtMS0xLTA_6977143f-18ff-4ac2-89de-022589b7caca">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTItMS0xLTA_e9b83283-c9e2-4950-a184-35c180037d9e">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTQtMS0xLTA_9d092a82-710f-4a60-80df-e27c6f5a3613">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTAtMS0xLTA_52e388d6-9373-475d-9e1c-40ccf0bd0726">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTItMS0xLTA_bfbfacb0-5d45-4756-be31-2de21ce506d7">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTQtMS0xLTA_f519846b-e791-4bd2-b1b1-0cc2a6d0f515">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTAtMS0xLTA_62c201ba-e7e2-4283-adc3-124971b3bff8">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTItMS0xLTA_236b7a76-6d2e-4ec3-82ad-288c88342596">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTQtMS0xLTA_ba09fcc2-976c-4953-a2f4-aabc29b951ef">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA4_0d0fd69c-3b89-49d7-8abc-62c1e8cbd926">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ib96e54056c2040cbaacb9760d9db43e4_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated April&#160;27,&#160;2021, announcing the financial results of Eli Lilly and Company for the quarter ended March 31, 2021, including, among other things, unaudited financial results for that period.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q121lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q121lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q121lillysalesandearningsp.htm">April 27</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q121lillysalesandearningsp.htm">, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 27, 2021</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q121lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic02ed1bcb4064e36b7f4fdff04553336_1"></div><div style="min-height:180pt;width:100%"><div style="text-align:right"><img alt="logoa311.jpg" src="logoa311.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">April 27, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lilly Corporate Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indianapolis, Indiana  46285</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.A. </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1.317.276.2000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:700;line-height:100%">www.lilly.com</font></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;</font><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Final</font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Refer to&#58;</font><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Molly McCully&#59; mccully_molly&#64;lilly.com&#59; (317) 478-5423 (Media)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Kevin Hern&#59; hern_kevin_r&#64;lilly.com&#59; (317) 277-1838 (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Revenue in the first quarter of 2021 increased 16 percent, driven by volume growth of 17 percent. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">First-quarter 2021 revenue grew 7 percent excluding revenue of $810.1&#160;million from COVID-19 antibodies and also excluding first-quarter 2020 revenue of approximately $250 million from increased customer buying patterns and patient prescription trends.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Key growth products, consisting of Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz, contributed 8 percentage points of revenue growth and represented approximately 46 percent of total revenue in the first quarter of 2021, or 52 percent of total revenue excluding revenue from COVID-19 antibodies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">First-quarter 2021 operating expenses increased 11 percent, driven primarily by higher research and development investments, including expenses of $220 million to develop COVID-19 therapies. Excluding investment in COVID-19 therapies, total operating expense growth was less than 3 percent.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Notable pipeline events included Emergency Use Authorization from the FDA for bamlanivimab and etesevimab together for the treatment of COVID-19, as well as positive data readouts for tirzepatide for type 2 diabetes, donanemab for Alzheimer's disease, mirikizumab for ulcerative colitis and baricitinib for alopecia areata.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">First-quarter 2021 earnings per share (EPS) decreased to $1.49 on a reported basis and increased to $1.87 on a non-GAAP basis. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2021 EPS guidance lowered to be in the range of $7.03 to $7.23 on a reported basis and adjusted to be in the range of $7.80 to $8.00 on a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:140%">Eli Lilly and Company (NYSE&#58; LLY) today announced financial results for the first quarter of 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:180pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.899%"><tr><td style="width:1.0%"></td><td style="width:46.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2020</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">6,805.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">5,859.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,355.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,456.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported<br></font><font style="font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%"><br></font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,701.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,471.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.87&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2021, non-GAAP measures exclude gains and losses on investments in equity securities and 2020 amounts have been reclassified for comparability. The company&#8217;s 2021 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company&#8217;s business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#34;In the first quarter of 2021, Lilly continued to advance our core business and make strategic progress to drive future growth, all while delivering hundreds of thousands of doses of our COVID-19 antibodies to patients and receiving new data for our monoclonal antibody therapies and new authorizations around the world to help fight the COVID-19 pandemic,&#34; said David A. Ricks, Lilly&#8217;s chairman and CEO. &#34;Our key growth products gained volume and share, helped millions of patients with significant diseases, and represented over half of our core business. We also had a remarkable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:180pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">quarter in R&#38;D beyond our COVID-19 efforts, reading out key late-stage successes with mirikizumab in ulcerative colitis, donanemab in Alzheimer's, tirzepatide in diabetes, and baricitinib in alopecia areata, while early-stage research continued to deliver and advance exciting clinical-stage molecules across our core therapeutic areas.&#8221; </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_4"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:140%;text-decoration:underline">Key Events Over the Last Three Months</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">COVID-19</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company took several steps in order to transition to supply bamlanivimab and etesevimab  for administration together in the U.S. for the treatment of COVID-19.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#9702;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.75pt">The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab together. This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and&#47;or hospitalization. As part of its previously reported collaboration with the company, Amgen began manufacturing etesevimab.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#9702;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.75pt">In connection with this transition, the company requested the FDA revoke the EUA for bamlanivimab alone. This request was not due to any new safety concern. The FDA subsequently revoked the EUA for bamlanivimab alone.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#9702;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.75pt">The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#9702;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.75pt">The U.S. government agreed to purchase a minimum of 100,000 doses of bamlanivimab and etesevimab together for a purchase price of $210 million. This purchase agreement was subsequently modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased. In addition, the purchase agreement with the U.S. government for bamlanivimab alone was terminated, and orders were cancelled for the remaining 350,856 doses that were scheduled to be delivered by the end of March 2021. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab and etesevimab together  reduced COVID-19 related hospitalizations and deaths by 87 percent in high-risk patients recently diagnosed with COVID-19.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced top-line data </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">from the expanded Phase 2 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent relative reduction in persistently high viral load at day 7 compared to placebo, meeting the primary endpoint.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Incyte announced results of a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC in patients hospitalized with COVID-19. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by day 28. However, in the study, treatment with baricitinib in addition to SoC resulted in a significant reduction in death from any cause by 38 percent by day 28.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Regulatory</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis. The FDA extended the action date to allow time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA. The Prescription Drug User Fee Act (PDUFA) action date has been extended three months to early in the third quarter of 2021.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Pfizer Inc. announced the outcome of the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 against. The companies will continue to work with the FDA as the agency continues its review of the tanezumab application.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Clinical</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that mirikizumab met the primary and all key secondary endpoints in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">a Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that the development program for mirikizumab will henceforth focus on the ulcerative colitis and Crohn&#8217;s disease indications. While the OASIS program generated positive results for mirikizumab with safety and efficacy similar to other IL-23p19s, the company no longer plans to submit mirikizumab for regulatory approval in psoriasis in any geography.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company presented results at the International Conference on Alzheimer's and Parkinson Diseases 2021 from a Phase 2 trial for donanemab that expanded on previously reported top-line data that found donanemab met its primary endpoint and showed significant slowing of decline compared to placebo on the integrated Alzheimer's Disease Rating Scale (iADRS), a composite measure of cognition and daily function, in patients with early symptomatic Alzheimer's disease.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced positive top-line results from three Phase 3 clinical trials of tirzepatide in adults with type 2 diabetes in terms of A1C and body weight reductions from baseline. The three trials compared tirzepatide to titrated insulin degludec, to placebo, both as an add-on to titrated insulin glargine, and to injectable semaglutide 1 mg.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Incyte announced top-line results from two Phase 3 studies evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata. In both studies, both doses of baricitinib met the primary efficacy endpoint at week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Business Development&#47;Other Developments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced several executive leadership transitions, including the appointment of Anat Ashkenazi as senior vice president and chief financial officer on February 9, 2021, the appointment of Edgardo Hernandez as senior vice president and president of manufacturing operations effective May 2, 2021, the appointment of Diogo Rau as senior vice president and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">chief information and digital officer effective May 17, 2021, and the appointment of Alonzo Weems as senior vice president, enterprise risk management and chief ethics and compliance officer effective June 27, 2021.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The Lilly board of directors elected Kimberly H. Johnson as a new member, effective February 16, 2021. She serves on both the Compensation Committee and the Ethics and Compliance Committee.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine&#47;threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Welldoc, Inc. announced a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions currently in development. Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar&#174; insulin management solution that integrates insulin dosing data for several Lilly insulins. Lilly will commercialize the pen platform, which will include the new app and Lilly's connected insulin pen solutions.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced a research collaboration and license agreement with Biolojic Design Ltd. that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the first quarter of 2021, worldwide revenue was $6.806 billion, an increase of 16 percent compared with the first quarter of 2020, driven by a 17 percent increase in volume and a 3 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 4 percent decrease due to lower realized prices. The company recognized worldwide revenue of $810.1&#160;million in the first quarter of 2021 for its COVID-19 antibodies. Key growth products, consisting of Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">contributed 8 percentage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">points of revenue growth and represented approximately 46 percent of total revenue for the first quarter of 2021, or</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">52 percent of total revenue excluding revenue from COVID-19 antibodies. The company estimates worldwide volume growth in the first quarter of 2020 was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased worldwide revenue by approximately $250 million, including approximately $200 million in the U.S. and approximately $50 million outside the U.S. Excluding $810.1 million of revenue in the first quarter of 2021 from COVID-19 antibodies and approximately $250 million of revenue in the first quarter of 2020 from increased customer buying patterns and patient prescription trends, worldwide revenue in the first quarter of 2021 grew by 7 percent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 18 percent, to $3.941 billion, driven by a 24 percent increase in volume, partially offset by a 6 percent decrease due to lower realized prices. The company recognized U.S. revenue of $650.6&#160;million in the first quarter of 2021 for COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in the U.S. declined by 1 percent, reflecting the impact of customer buying patterns and patient prescription trends in the first quarter of 2020 resulting from the COVID-19 pandemic. Increased U.S. volume for certain key growth products, including Trulicity, Taltz, Verzenio, Retevmo, Emgality, Jardiance and Olumiant was partially offset by lower volume for other products, including Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">. The decrease in realized prices in the U.S. in the first quarter of 2021 was primarily driven by increased rebates to gain broad commercial access for Taltz, partially offset by modest list price increases. Segment mix was not a major driver of U.S. price performance in the first quarter of 2021, as increased utilization in more highly-rebated government segments was offset by lower utilization in the 340B segment, primarily for the diabetes portfolio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. increased 13 percent, to $2.864 billion, driven by a 9 percent increase in volume and a 6 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 2 percent decrease due to lower realized prices. The increase in volume outside the U.S. was driven primarily by increased volume for key growth products, including Olumiant, Tyvyt, Verzenio, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Trulicity, Taltz, Jardiance, Emgality, Cyramza and Retevmo, as well as $159.5&#160;million of revenue recognized for COVID-19 antibodies. Revenue outside the U.S. was also impacted by volume gains for Alimta, partially offset by decreased volume for Cialis, Forteo, Cymbalta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">. The decrease in realized prices outside the U.S. was driven primarily by Trulicity, Olumiant and Forteo. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin increased 6 percent, to $4.927 billion, in the first quarter of 2021 compared with the first quarter of 2020. Gross margin as a percent of revenue was 72.4 percent, a decrease of 6.9 percentage points compared with the first quarter of 2020. The decrease in gross margin percent was primarily due to unfavorable product mix driven by sales of COVID-19 antibodies, the unfavorable effect of foreign exchange rates on international inventories sold, higher amortization of intangibles expense related to Retevmo, charges resulting from excess inventory of COVID-19 antibodies due in part to the termination of the purchase agreement with the U.S. government for bamlanivimab following discontinuation of the product's distribution on its own in the U.S., and, to a lesser extent, the impact of lower realized prices on revenue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Total operating expenses in the first quarter of 2021, defined as the sum of research and development and marketing, selling, and administrative expenses, increased 11 percent to $3.261 billion compared with the first quarter of 2020. Research and development expenses increased 21 percent to $1.685 billion, or 24.8 percent of revenue, driven primarily by approximately $220 million of research and development expenses for COVID-19 antibody therapies and baricitinib, as well as higher research and development expenses for late-stage assets. Marketing, selling, and administrative expenses increased 2 percent to $1.576 billion. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the first quarter of 2021, the company recognized acquired in-process research and development charges of $299.3 million related to business development transactions with Rigel Pharmaceuticals, Inc., Precision BioSciences, Inc., Merus N.V., and Asahi Kasei Pharma Corporation. In the first quarter of 2020, the company recognized acquired in-process research and development charges of $52.3 million related to a business development transaction with Sitryx Therapeutics Ltd. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the first quarter of 2021, the company recognized asset impairment, restructuring and other special charges of $211.6 million. These charges related primarily to an intangible asset impairment resulting from the decision to sell the rights to QBREXZA</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. In the first quarter of 2020, the company recognized asset impairment, restructuring and other special charges of $59.9 million, related primarily to acquisition and integration costs associated with the acquisition of Dermira, Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income in the first quarter of 2021 was $1.155 billion, compared to</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> $1.591 billion i</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">n the first quarter of 2020. The decrease in operating income was primarily driven by higher research and development expenses, higher acquired in-process research and development charges, and higher asset impairment, restructuring and other special charges, partially offset by higher gross margin. Operating margin, defined as operating income as a percent of revenue, was 17.0 percent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income was $321.1 million in the first quarter of 2021, compared with other income of $89.1 million in the first quarter of 2020. The increase in other income was driven primarily by higher net gains on investment securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 8.2 percent in the first quarter of 2021, as compared with 13.3 percent in the first quarter of 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected in the first quarter of 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the first quarter of 2021, net income and earnings per share were $1.355&#160;billion and $1.49, respectively, compared with net income of $1.457&#160;billion and earnings per share of $1.60 in the first quarter of 2020. The decrease in net income and earnings per share in the first quarter of 2021 was primarily driven by lower operating income, partially offset by higher other income and lower income tax expense.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_10"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">First-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, first-quarter 2021 gross margin increased 9 percent, to $5.134 billion compared with the first quarter of 2020. Gross margin as a percent of revenue was 75.4 percent, a decrease of 4.9 percentage points. The decrease in gross margin percent was primarily due to unfavorable product mix driven by sales of COVID-19 antibodies, the unfavorable effect of foreign exchange rates on international inventories sold, and, to a lesser extent, the impact of lower realized prices on revenue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income on a non-GAAP basis increased $111.8 million, or 6 percent, to $1.873 billion in the first quarter of 2021 compared with the first quarter of 2020, due primarily to higher gross margin, partially offset by higher research and development expenses. Operating margin was 27.5 percent on a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income was $34.6 million in the first quarter of 2021, compared with other expense of $72.6 million in the first quarter of 2020. The increase in other income was driven primarily by a favorable patent settlement in Europe for Alimta in the first quarter of 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 10.8 percent in the first quarter of 2021, as compared with 12.9 percent in the first quarter of 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected in the first quarter of 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, in the first quarter of 2021 net income increased 16 percent, to $1.702 billion, while earnings per share increased 16 percent, to $1.87, compared with $1.471 billion and $1.61, respectively, in the first quarter of 2020. The increase in net income and earnings per share was driven primarily by higher operating income and higher other income.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information&#34; table later in this press release.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Quarter</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2020</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(7)%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Acquired in-process research and development</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">COVID-19 antibodies excess inventory charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net gains on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.87</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">16%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_25"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.182%"><tr><td style="width:1.0%"></td><td style="width:40.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Selected Revenue Highlights</font></div><div style="margin-top:1pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">First Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,452.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,229.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">810.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">617.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">695.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(11)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">559.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">560.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(0)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">403.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">443.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">321.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">315.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">312.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">267.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">269.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">188.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">43%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Basaglar</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">246.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">303.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">240.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">239.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Forteo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">198.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">272.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(27)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">193.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">139.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">39%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">119.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">74.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">61%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">109.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">57.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">91%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,805.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5,859.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations                                                        </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR                        NM &#8211; not meaningful                                                                               </font></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Impact of COVID-19 on First-Quarter 2020 Revenue</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the first quarter of 2020, the company estimated that revenue for many of its products was  favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased revenue by approximately $250 million worldwide, including approximately $200 million in the U.S. and approximately $50 million outside the U.S. The company believes that this increase in U.S. revenue primarily impacted its portfolio of diabetes medicines, with estimated increases of approximately $70 million to $80 million for insulin products and approximately $30 million to $40 million for Trulicity. The company also estimated that U.S. revenue for Taltz was favorably impacted by approximately $20 million to $25 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">First-quarter 2021 worldwide Trulicity revenue was $1.452 billion, an increase of 18 percent compared with the first quarter of 2020. U.S. revenue increased 20 percent, to $1.117 billion, driven by increased demand, partially offset by lower realized prices. Trulicity's lower realized prices in the U.S. were primarily due to higher contracted rebates, partially offset by a favorable segment mix that reflected lower utilization in the 340B segment, and modest list price increases. Revenue outside the U.S. was $335.7 million, an increase of 12 percent, driven by increased volume and, to a lesser extent, favorable foreign exchange rates, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Humalog revenue decreased 11 percent compared with the first quarter of 2020, to $617.0 million. Revenue in the U.S. decreased 17 percent, to $332.7 million, driven by lower realized prices as higher contracted rebates and discounts were partially offset by lower utilization in the 340B segment. Revenue outside the U.S. decreased 4 percent, to $284.4 million, driven by decreased volume, partially offset by the favorable impact of foreign exchange rates.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Alimta</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Alimta revenue remained flat compared with the first quarter of 2020, at $559.0 million. U.S. revenue decreased 19 percent, to $261.1&#160;million, primarily driven by lower volume as a result of customer buying patterns and, to a lesser extent, lower realized prices. Revenue outside the U.S. increased 26 percent to $297.8 million, primarily driven by increased volume in Germany and, to a lesser extent, the favorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects volume declines in the second half of 2021 for Alimta as a result of the anticipated entry of generic competition due to the loss of patent exclusivity in Japan and major European markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Taltz revenue decreased 9 percent compared with the first quarter of 2020, to $403.2&#160;million. U.S. revenue decreased 24 percent, to $249.6&#160;million, primarily due to increased rebates to gain commercial access which resulted in lower realized prices, partially offset by increased demand. Revenue outside the U.S. increased 32 percent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $153.6 million, primarily driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humulin</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Humulin revenue increased 2 percent compared with the first quarter of 2020, to $321.7 million. U.S. revenue increased 2 percent, to $219.0 million, driven by higher realized prices, partially offset by decreased demand. Revenue outside the U.S. increased 1 percent, to $102.7 million, primarily due to the favorable impact of foreign exchange rates and higher realized prices, largely offset by decreased volume. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company&#8217;s worldwide Jardiance revenue during the first quarter of 2021 was $312.0 million, an increase of 17 percent compared with the first quarter of 2020. U.S. revenue increased 5 percent, to $151.2 million, driven by increased demand. Revenue outside the U.S. was $160.8 million, an increase of 31 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. Jardiance is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Verzenio revenue increased 43 percent compared with the first quarter of 2020, to $269.0 million. U.S. revenue was $172.8 million, an increase of 34 percent, primarily driven by increased demand and, to a lesser extent, higher realized prices. Revenue outside the U.S. was $96.2 million, an increase of 64 percent, primarily driven by increased volume.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Basaglar</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Basaglar revenue was $246.6 million, a decrease of 19 percent compared with the first quarter of 2020. U.S. revenue decreased</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">24 percent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> to $175.2 million, driven by decreased demand caused by competitive pressures and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 3 percent, to $71.4&#160;million, driven by lower realized prices and decreased volume, partially offset by the favorable impact of foreign exchange rates. Basaglar is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as cost of sales payments made to Boehringer Ingelheim for royalties.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Cyramza</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Cyramza revenue was $240.5&#160;million, an increase of 1 percent compared with the first quarter of 2020. U.S. revenue was $80.2&#160;million, a decrease of 10 percent, primarily driven by decreased demand and lower realized prices. Revenue outside the U.S. was </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$160.3&#160;million, an increase of 7 percent, driven by the favorable impact of foreign exchange rates and increased volume. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Forteo</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Forteo revenue decreased 27 percent compared with the first quarter of 2020, to $198.5 million. U.S. revenue decreased 20 percent, to $97.7 million, driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. decreased 33 percent to $100.8&#160;million, driven by decreased volume and, to a lesser extent, lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects further volume declines for Forteo as a result of the anticipated entry of generic and biosimilar competition due to the loss of patent exclusivity in the U.S., Japan and major European markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, worldwide Olumiant revenue increased 39 percent compared with first quarter of 2020, to $193.8 million. U.S. revenue was $24.7 million. Revenue outside the U.S. was $169.1 million, an increase of 32 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, Emgality generated worldwide revenue of $119.5 million, an increase of 61 percent compared with the first quarter of 2020. U.S. revenue was $101.5 million, an increase of 51 percent driven by higher realized prices and, to a lesser extent, increased demand. Revenue outside of the U.S. was $18.0 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Tyvyt</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, the company's Tyvyt revenue in China was $109.7 million, an increase of 91 percent compared with the first quarter of 2020. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Tyvyt is part of the company&#8217;s alliance with Innovent. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Retevmo</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first quarter of 2021, Retevmo generated U.S. revenue of $16.8 million. Retevmo was approved by the FDA and launched in the U.S. during the second quarter of 2020. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_34"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2021 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">The company has updated certain elements of its 2021 financial guidance on a reported and a non-GAAP basis. Earnings per share for 2021 are now expected to be in the range of $7.03 to $7.23 on a reported basis and $7.80 to $8.00 on a non-GAAP basis. The update to the company's 2021 financial guidance on a reported basis reflects adjustments shown in the reconciliation table below. The update to the company's 2021 financial guidance on a non-GAAP basis reflects primarily lower expected revenue from COVID-19 antibody sales  due to lower expected demand and higher expected research and development expenses. </font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.547%"><tr><td style="width:1.0%"></td><td style="width:55.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.995%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2021<br>Expectations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">% Change vs 2020</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.03 to $7.23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">4% to 6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.50</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.26</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies excess inventory charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.07</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Net gains on investments in equity securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.25)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.80 to $8.00</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">15% to 18%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding                                      <br></font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company now anticipates 2021 revenue to be between $26.6 billion and $27.6 billion, including an estimated $1 billion to $1.5 billion of revenue from COVID-19 therapies. Revenue growth is additionally expected to be driven by volume from key growth products, including Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt and Retevmo, as well as by COVID-19 therapies. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity. The company expects mid-single digit net price declines globally in 2021. In the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;19</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">U.S., the company expects low-to-mid-single digit net price declines, driven primarily by increased rebates to maintain broad commercial access and segment mix, partially offset by lower utilization in the 340B segment. Outside the U.S., the company expects net price declines in China, Japan, and Europe.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin as a percent of revenue for 2021 is still expected to be approximately 77 percent on a reported basis and approximately 79 percent on a non-GAAP basis. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses for 2021 are still expected to be in the range of $6.2 billion to $6.4 billion. Research and development expenses for 2021 are now expected to be in the range of $6.9 billion to $7.1 billion, reflecting additional investments in potential therapies for Alzheimer's disease and  approximately $400 million to $500 million of continued investment in COVID-19 therapies. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating margin for 2021 is now expected to be approximately 26 percent on a reported basis and approximately 31 percent on a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) for 2021 is now expected to be income in the range of $150 million to $250 million on a reported basis and expense in the range of $100 million to $200 million on a non-GAAP basis. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The 2021 effective tax rate is now expected to be approximately 13 percent on both a reported basis and a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company&#8217;s 2021 financial guidance&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2021 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$26.5 to $28.0 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$26.6 to $27.6 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 77%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 79%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.2 to $6.4 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.5 to $6.7 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.9 to $7.1 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(300) to $(200) million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$150 to $250 million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(300) to $(200) million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(200) to $(100) million</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 15%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13%</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.10 to $7.75</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.03 to $7.23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.75 to $8.40</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.80 to $8.00</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 26%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 32%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 31%</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></td></tr></table></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_37"></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the first-quarter 2021 financial results conference call through a link on Lilly&#8217;s website at www.lilly.com. The conference call will begin at 9&#58;00 a.m. Eastern time (ET) today and will be available for replay via the website.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management&#8217;s current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;intend&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221;, &#8220;target&#8221;, &#8220;anticipate&#8221; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the impact of the evolving COVID-19 pandemic and the global response thereto&#59; uncertainties related to the company&#8217;s efforts to develop potential treatments for COVID-19&#59; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact of acquisitions and business development transactions and related integration costs&#59; the expiration of intellectual property protection for certain of the company&#8217;s products and competition from generic and&#47;or biosimilar products&#59; the company&#8217;s ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company&#8217;s pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company&#8217;s IT systems, networks, and facilities, or those of third parties with whom the company&#8217;s shares its data&#59; unexpected safety or efficacy concerns associated with the company&#8217;s products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions related to our facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; regulatory changes or other developments&#59; regulatory actions regarding currently marketed products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates, and inflation&#59; changes in tax law, tax rates, or events that differ from the company&#8217;s assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; the impact of global macroeconomic conditions and trade disruptions or disputes&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; and regulatory compliance problems or government investigations. For additional information about the factors that could cause actual results to differ materially from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;22</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements, please see the company&#8217;s latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin glargine injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tadalafil, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cymbalta (duloxetine, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (teriparatide of recombinant DNA origin injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (human insulin of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">QBREXZA</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (Glycopyrronium cloth, Dermira)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Employment Information</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.842%"><tr><td style="width:1.0%"></td><td style="width:28.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Employees</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34,690</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34,960</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;23</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results  (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.970%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,805.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,878.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,215.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">55%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,684.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,392.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,576.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,549.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">299.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">59.9&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,155.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,590.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(27)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(82.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(78.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">403.4&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">167.3&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">321.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,476.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,679.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(12)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(46)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,355.3&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,456.5&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.850&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.740&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">912,419&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,713&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;24</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic02ed1bcb4064e36b7f4fdff04553336_43"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:21.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended <br>March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31, 2020</font></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,878.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(207.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,671.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,215.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(58.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,156.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">299.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(299.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">52.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">211.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">59.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">321.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">89.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(161.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(72.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">121.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">206.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">223.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">217.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,355.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">346.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,701.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,456.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,471.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.38</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company&#8217;s non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company&#8217;s reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company&#8217;s ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;25</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the three months ended March 31, 2021, include the following&#58; </font></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(125.7)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(81.5)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(207.2)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(299.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(299.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(286.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(55.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">85.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">236.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">241.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(230.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">346.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.38</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to business development transactions with Rigel Pharmaceuticals, Inc., Precision BioSciences, Inc., Merus N.V., and Asahi Kasei Pharma Corporation.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily an intangible asset impairment resulting from the decision to sell the rights to QBREXZA, charges resulting from excess inventory due in part to the discontinuation of bamlanivimab for use on its own, as well as acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;26</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the three months ended March 31, 2020, include the following&#58;</font></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.528%"><tr><td style="width:1.0%"></td><td style="width:34.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(54.4)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(58.6)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(52.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(59.9)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(161.7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(161.7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(34.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(5.5)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(127.7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">14.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.01</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to a business development transaction with Sitryx. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily acquisition and integration costs associated with the acquisition of Dermira, Inc. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;27</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20210427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20210427" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20210427">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210427_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210427_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lly-20210427_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210427.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lly-20210427_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210427.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="ice15b6a84fc343c7b5e0a60d087fac21_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a53a1ec3-095b-4a11-ba31-5212cb06d43a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_DocumentType_a53a1ec3-095b-4a11-ba31-5212cb06d43a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_229ea3b0-c0e0-44bf-b0ae-3a07424c9b9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_DocumentPeriodEndDate_229ea3b0-c0e0-44bf-b0ae-3a07424c9b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16a3f7ea-7970-4524-a332-85a9eed5facb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16a3f7ea-7970-4524-a332-85a9eed5facb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d3be7e87-07bd-40dd-9de1-74ad95b0a9dc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityFileNumber_d3be7e87-07bd-40dd-9de1-74ad95b0a9dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a8b2781e-a358-4bb2-9dc3-501bc3047a83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityTaxIdentificationNumber_a8b2781e-a358-4bb2-9dc3-501bc3047a83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3b981566-bd84-4e58-a373-f0b7a932b46e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressAddressLine1_3b981566-bd84-4e58-a373-f0b7a932b46e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0f494335-389b-460f-b172-c968605c795b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressCityOrTown_0f494335-389b-460f-b172-c968605c795b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e4db9532-ecb6-4bc0-9a63-f24dee8613cc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressStateOrProvince_e4db9532-ecb6-4bc0-9a63-f24dee8613cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_03c0fcbc-038d-4f81-b3ca-ededbc4c05f0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressPostalZipCode_03c0fcbc-038d-4f81-b3ca-ededbc4c05f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_41842596-c63b-4517-a349-659f1fa1a30a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_CityAreaCode_41842596-c63b-4517-a349-659f1fa1a30a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_58de74dc-1fd5-4510-841d-36f886c083a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_LocalPhoneNumber_58de74dc-1fd5-4510-841d-36f886c083a0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_dacbf9e9-3114-40f7-a1f9-d477b12d1fc8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_WrittenCommunications_dacbf9e9-3114-40f7-a1f9-d477b12d1fc8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_00fdd415-50d7-453d-9772-d65021ac5bf0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_SolicitingMaterial_00fdd415-50d7-453d-9772-d65021ac5bf0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_292d5e9a-185e-417d-a05f-254492e82a7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_PreCommencementTenderOffer_292d5e9a-185e-417d-a05f-254492e82a7e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3f25714b-1ccb-45ea-aaab-bc54d7f79ea6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3f25714b-1ccb-45ea-aaab-bc54d7f79ea6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c76474cb-375b-40e9-8892-fb417043340b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityEmergingGrowthCompany_c76474cb-375b-40e9-8892-fb417043340b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1eb66604-d717-4fb4-aaec-c1bc48752750" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_Security12bTitle_1eb66604-d717-4fb4-aaec-c1bc48752750" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d45bfee4-a1fb-41de-844e-dc9aa837f385" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_TradingSymbol_d45bfee4-a1fb-41de-844e-dc9aa837f385" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7cfa2491-ec9b-411e-ae4b-e137ce468947" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_SecurityExchangeName_7cfa2491-ec9b-411e-ae4b-e137ce468947" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc7609cd-2d0f-49a3-bf3a-317ab43a66b9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityRegistrantName_bc7609cd-2d0f-49a3-bf3a-317ab43a66b9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fc379c6a-661d-4496-9d80-ad5e188c54ea" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityCentralIndexKey_fc379c6a-661d-4496-9d80-ad5e188c54ea" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3719e358-44d2-44ff-bcc1-0a3f6673ef02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_AmendmentFlag_3719e358-44d2-44ff-bcc1-0a3f6673ef02" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd62f28d-f529-444b-bdd9-8eee2df22832_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:to="loc_us-gaap_ClassOfStockDomain_bd62f28d-f529-444b-bdd9-8eee2df22832_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:to="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5b372b3d-b037-4f36-83e7-37720d18fb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_us-gaap_CommonClassAMember_5b372b3d-b037-4f36-83e7-37720d18fb54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_f6923847-a5de-4070-a5f1-2e4b6ba464c9" xlink:href="lly-20210427.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.000NotesDueJune22022Member_f6923847-a5de-4070-a5f1-2e4b6ba464c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_9142c9bf-26f7-4456-9539-e48dc67ac6f0" xlink:href="lly-20210427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A718NotesDueJune12025Member_9142c9bf-26f7-4456-9539-e48dc67ac6f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_ecb862ec-a83f-40e9-8f69-aaa85038c9f0" xlink:href="lly-20210427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.625NotesDueJune22026Member_ecb862ec-a83f-40e9-8f69-aaa85038c9f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_ec17a111-414e-4d94-923b-ffd6302a6a8b" xlink:href="lly-20210427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A2.125NotesDueJune32030Member_ec17a111-414e-4d94-923b-ffd6302a6a8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_4b4d7a6c-33b5-4d2e-99a9-b726f956541d" xlink:href="lly-20210427.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A625Notesdue2031Member_4b4d7a6c-33b5-4d2e-99a9-b726f956541d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_a0289fb7-aa40-48ca-b9cc-4d7d07af0988" xlink:href="lly-20210427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_a0289fb7-aa40-48ca-b9cc-4d7d07af0988" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_dbe47661-3496-45ca-be9a-cd695a206a5f" xlink:href="lly-20210427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.700Notesdue2049Member_dbe47661-3496-45ca-be9a-cd695a206a5f" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lly-20210427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_be9a63c2-e01e-4664-80fc-95bcfe766cdd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_56679152-6c2e-43c0-9ded-0a49d06f637d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_62060a04-74e1-4370-b6ff-c06fac3a6e09_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20210427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_32972c77-ee57-4220-ac04-94c26e69de80_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_71b362ec-106e-426c-85f7-e7438edb08ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_9b59c179-e7d5-4ca8-b842-311b0ee823ec_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20210427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ff840c04-f8a5-4031-b0dd-8cd672415075_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_dc955423-16e4-40a3-b555-8f5ee1565314_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_688ec9ac-50b9-4364-923e-28e84f589804_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bbf3b5b4-970e-4c5a-a822-516244d27306_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8956874d-1d2e-47f5-a975-04fd6b42397e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_071147ff-9bea-4506-bc04-1c69a7c40af0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0f051d71-e8b3-4c63-876f-5dd182655fd9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8dd6c050-c32b-4cc7-b1c9-547fdc127619_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_7d9d455b-fdae-4561-a6ad-e6f15ebdee45_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20210427.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_2ba6ff5a-6677-46c3-802d-7c992eb568de_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_173f63a9-5ae3-4bca-be9d-684e60bd9391_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e9503527-a392-40ae-a724-6ab2a3039322_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_357987f0-64a4-48c5-8a17-96d3fb524c24_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20210427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3d719ba3-abd0-459f-abb7-2422cd5bb0a7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9daa1546-aef4-4e63-bbb9-a98640f643a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_1c0f03f1-c167-47fb-9441-6279390a9139_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20210427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_12947dd1-152b-4993-aefb-4cfc9bdee4fb_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20210427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_41382799-590c-4a15-b699-809986eb8d77_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2f799d89-75dc-49b1-a4b8-8e8dd0eab517_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_aa5de3ae-b09c-441f-8c9c-ff0bd7a9fcf3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2f8de679-0c68-4d88-92aa-f577456add65_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_605a9644-9b15-4c11-a18f-e17f44ba4bd3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_71929106-533b-4d66-90e9-7d5cbd14fd2e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_3dd790c1-9d06-47d0-9b43-7c61abb6c118_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_79720404-4d49-403f-a524-6dfcd63f437e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b4b1ad49-9fc1-4ce8-a439-b82a222346aa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3900b2e3-3e1e-4f2a-b9ff-9a61803ecb97_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_dcadca77-7813-4d79-adc1-72a66895d1bc_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20210427.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_78dffa3c-9ebb-4ca5-8adc-00c4c3633709_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lly-20210427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:99e6c62f-a069-463f-b080-96cd959ce0b1,g:13bf1763-6fd0-49c1-9766-a165c17c3908-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210427.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3afd0741-8aa0-4314-8e0c-91385b04c9f4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3afd0741-8aa0-4314-8e0c-91385b04c9f4" xlink:to="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd62f28d-f529-444b-bdd9-8eee2df22832" xlink:to="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5b372b3d-b037-4f36-83e7-37720d18fb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_us-gaap_CommonClassAMember_5b372b3d-b037-4f36-83e7-37720d18fb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_f6923847-a5de-4070-a5f1-2e4b6ba464c9" xlink:href="lly-20210427.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.000NotesDueJune22022Member_f6923847-a5de-4070-a5f1-2e4b6ba464c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_9142c9bf-26f7-4456-9539-e48dc67ac6f0" xlink:href="lly-20210427.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A718NotesDueJune12025Member_9142c9bf-26f7-4456-9539-e48dc67ac6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_ecb862ec-a83f-40e9-8f69-aaa85038c9f0" xlink:href="lly-20210427.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.625NotesDueJune22026Member_ecb862ec-a83f-40e9-8f69-aaa85038c9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_ec17a111-414e-4d94-923b-ffd6302a6a8b" xlink:href="lly-20210427.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A2.125NotesDueJune32030Member_ec17a111-414e-4d94-923b-ffd6302a6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_4b4d7a6c-33b5-4d2e-99a9-b726f956541d" xlink:href="lly-20210427.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A625Notesdue2031Member_4b4d7a6c-33b5-4d2e-99a9-b726f956541d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_a0289fb7-aa40-48ca-b9cc-4d7d07af0988" xlink:href="lly-20210427.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_a0289fb7-aa40-48ca-b9cc-4d7d07af0988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_dbe47661-3496-45ca-be9a-cd695a206a5f" xlink:href="lly-20210427.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79e9fc96-c0b9-4026-83f7-f07c978b564d" xlink:to="loc_lly_A1.700Notesdue2049Member_dbe47661-3496-45ca-be9a-cd695a206a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5c89bfb8-4201-40b8-ae42-535dac5f3af2" xlink:to="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a53a1ec3-095b-4a11-ba31-5212cb06d43a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_DocumentType_a53a1ec3-095b-4a11-ba31-5212cb06d43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_229ea3b0-c0e0-44bf-b0ae-3a07424c9b9d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_DocumentPeriodEndDate_229ea3b0-c0e0-44bf-b0ae-3a07424c9b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16a3f7ea-7970-4524-a332-85a9eed5facb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16a3f7ea-7970-4524-a332-85a9eed5facb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d3be7e87-07bd-40dd-9de1-74ad95b0a9dc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityFileNumber_d3be7e87-07bd-40dd-9de1-74ad95b0a9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a8b2781e-a358-4bb2-9dc3-501bc3047a83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityTaxIdentificationNumber_a8b2781e-a358-4bb2-9dc3-501bc3047a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3b981566-bd84-4e58-a373-f0b7a932b46e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressAddressLine1_3b981566-bd84-4e58-a373-f0b7a932b46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0f494335-389b-460f-b172-c968605c795b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressCityOrTown_0f494335-389b-460f-b172-c968605c795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e4db9532-ecb6-4bc0-9a63-f24dee8613cc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressStateOrProvince_e4db9532-ecb6-4bc0-9a63-f24dee8613cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_03c0fcbc-038d-4f81-b3ca-ededbc4c05f0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityAddressPostalZipCode_03c0fcbc-038d-4f81-b3ca-ededbc4c05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_41842596-c63b-4517-a349-659f1fa1a30a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_CityAreaCode_41842596-c63b-4517-a349-659f1fa1a30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_58de74dc-1fd5-4510-841d-36f886c083a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_LocalPhoneNumber_58de74dc-1fd5-4510-841d-36f886c083a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_dacbf9e9-3114-40f7-a1f9-d477b12d1fc8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_WrittenCommunications_dacbf9e9-3114-40f7-a1f9-d477b12d1fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_00fdd415-50d7-453d-9772-d65021ac5bf0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_SolicitingMaterial_00fdd415-50d7-453d-9772-d65021ac5bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_292d5e9a-185e-417d-a05f-254492e82a7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_PreCommencementTenderOffer_292d5e9a-185e-417d-a05f-254492e82a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3f25714b-1ccb-45ea-aaab-bc54d7f79ea6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3f25714b-1ccb-45ea-aaab-bc54d7f79ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c76474cb-375b-40e9-8892-fb417043340b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityEmergingGrowthCompany_c76474cb-375b-40e9-8892-fb417043340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1eb66604-d717-4fb4-aaec-c1bc48752750" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_Security12bTitle_1eb66604-d717-4fb4-aaec-c1bc48752750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d45bfee4-a1fb-41de-844e-dc9aa837f385" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_TradingSymbol_d45bfee4-a1fb-41de-844e-dc9aa837f385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7cfa2491-ec9b-411e-ae4b-e137ce468947" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_SecurityExchangeName_7cfa2491-ec9b-411e-ae4b-e137ce468947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc7609cd-2d0f-49a3-bf3a-317ab43a66b9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityRegistrantName_bc7609cd-2d0f-49a3-bf3a-317ab43a66b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fc379c6a-661d-4496-9d80-ad5e188c54ea" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_EntityCentralIndexKey_fc379c6a-661d-4496-9d80-ad5e188c54ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3719e358-44d2-44ff-bcc1-0a3f6673ef02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_bcfff048-30a4-4c63-bb40-7a920e80dcfd" xlink:to="loc_dei_AmendmentFlag_3719e358-44d2-44ff-bcc1-0a3f6673ef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logoa311.jpg
<TEXT>
begin 644 logoa311.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lly-20210427_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20210427"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20210427.xsd" xlink:type="simple"/>
    <context id="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="i282cc034e78b44beb71f281568135298_D20210427-20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF80L2ZyYWc6MDU3MjNiM2Q2OTIwNDRkZjhiNmJlZjNlYWZjOWIzNmYvdGFibGU6NWU5YzRmOTlmNGRlNGI2OTlhMmQyOTdjZTFlMDQwYWQvdGFibGVyYW5nZTo1ZTljNGY5OWY0ZGU0YjY5OWEyZDI5N2NlMWUwNDBhZF8yLTEtMS0xLTA_83e8637f-67a6-4b06-9dd8-c9e14b4d7921">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF80L2ZyYWc6MDU3MjNiM2Q2OTIwNDRkZjhiNmJlZjNlYWZjOWIzNmYvdGFibGU6NWU5YzRmOTlmNGRlNGI2OTlhMmQyOTdjZTFlMDQwYWQvdGFibGVyYW5nZTo1ZTljNGY5OWY0ZGU0YjY5OWEyZDI5N2NlMWUwNDBhZF81LTEtMS0xLTA_5f81be14-efa4-47c0-8c0f-edc8bc74da19">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA5_4541ec3f-7cef-4e09-9137-6bd981af1a29">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xNjU_39684d8c-0b8d-4a72-a4b2-bd6de63e168c">2021-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjEw_6857c540-cd98-4b58-8e35-85b4fdf1100a">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTAtMS0xLTA_08141a1c-07d0-41c0-96da-76b191e1e647">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTItMS0xLTA_2bd8f4d0-3aab-4353-b338-30ba53910897">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZWUxOTY4ZDdhN2I2NDEwZmI1YjVhZmNhMzQ4ZGEwOGQvdGFibGVyYW5nZTplZTE5NjhkN2E3YjY0MTBmYjViNWFmY2EzNDhkYTA4ZF8wLTQtMS0xLTA_53ff2662-bda0-4515-811c-b92b612da502">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18wLTAtMS0xLTA_fb8a99d1-39b5-4a15-a742-83fabd24e190">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTAtMS0xLTA_aae6206c-b121-45d7-875d-f4a3b94f2842">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTEtMS0xLTA_22bfc361-2900-4d24-92b7-8d2e2f917638">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6ZTk2MjU4NjgxOGU3NDYzMGJiMTRiMTc4ZTE3MTcxY2MvdGFibGVyYW5nZTplOTYyNTg2ODE4ZTc0NjMwYmIxNGIxNzhlMTcxNzFjY18xLTItMS0xLTA_4ea02e57-0d02-47f6-96c0-8b31c50af898">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA2_458e8e96-7b95-4f4c-b6b5-4c3e6efbceae">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA3_6ca47db7-30d0-4471-a72d-1c7ddf4087f7">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6NWZkZGFmZGIxZWViNDU2NGFlMWMxMzdiOGE0YWM4YTQvdGFibGVyYW5nZTo1ZmRkYWZkYjFlZWI0NTY0YWUxYzEzN2I4YTRhYzhhNF8wLTAtMS0xLTA_fc5229d2-acb9-49e8-b123-500816f0144e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6NDIyNWM5NzQwYzkwNGFhOGE4YzUzMzBiYzIxZWNlODgvdGFibGVyYW5nZTo0MjI1Yzk3NDBjOTA0YWE4YThjNTMzMGJjMjFlY2U4OF8wLTAtMS0xLTA_75f1c3e6-a619-4803-90df-f4d46c9d0bb6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6OTg5NzA1ZDE1YzM0NDY3YWIzZjkzMDBjNjU0MmIzZjMvdGFibGVyYW5nZTo5ODk3MDVkMTVjMzQ0NjdhYjNmOTMwMGM2NTQyYjNmM18wLTAtMS0xLTA_e968f240-41d9-4fde-9128-60225e50c5c4">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6YjNkMzdkNmFmNTMwNDQ2Y2IwODc4MmVmNDQ5YjczMWQvdGFibGVyYW5nZTpiM2QzN2Q2YWY1MzA0NDZjYjA4NzgyZWY0NDliNzMxZF8wLTAtMS0xLTA_9284ebff-ce51-444d-8f82-baa09f6e9d69">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTAtMS0xLTA_781e81f3-487f-4907-803d-c4b25708ad27">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTItMS0xLTA_2df1813a-0254-4e57-ac07-28f71d3607c6">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i141aa9a4e88c4b6db7f10aa17eb500c0_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8xLTQtMS0xLTA_a03ed442-29d7-404e-b221-f2fc55f4f2d5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTAtMS0xLTA_f21a13b9-097c-40e7-8e6c-c5d335555211">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTItMS0xLTA_53fdee60-f5b3-46e3-b90b-0d5f1ca81100">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie026dad11eb944238fce3ff0fcb9b552_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8yLTQtMS0xLTA_9e2b0ebb-f8d4-4369-9930-8a26d0ab0d57">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTAtMS0xLTA_046eaa84-4b6a-442e-853d-039468aaa5d6">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTItMS0xLTA_3b89d4d7-854e-48cc-bcca-63f666eacbdf">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0044a97d802c47cdae972693061ffeb8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV8zLTQtMS0xLTA_2648550d-3d5d-4603-ade2-b50e66fc2ded">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTAtMS0xLTA_a583f1aa-9aad-4a79-9303-ddab6fa171e9">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTItMS0xLTA_18c71fa0-3d2e-4d70-a9cb-56118231a2fd">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia5a15024a46c4dde8e074cf1f6f77e4a_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV80LTQtMS0xLTA_be157bc7-b8d6-40a9-8df0-dd76500e9fd0">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTAtMS0xLTA_ecd6e461-5a27-4450-8b5f-854462aabe88">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTItMS0xLTA_43e7b7e8-e9ba-40f3-9d81-49b7609b32c3">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idbe57f6c081341b29d75afee45e859a8_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV81LTQtMS0xLTA_adf41714-1cdf-4a37-b670-3d1b16032cda">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTAtMS0xLTA_6977143f-18ff-4ac2-89de-022589b7caca">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTItMS0xLTA_e9b83283-c9e2-4950-a184-35c180037d9e">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i562dde3d081945ebaaaf0e9769403b3e_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV82LTQtMS0xLTA_9d092a82-710f-4a60-80df-e27c6f5a3613">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTAtMS0xLTA_52e388d6-9373-475d-9e1c-40ccf0bd0726">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTItMS0xLTA_bfbfacb0-5d45-4756-be31-2de21ce506d7">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id0f1443ddb814d29a74586ae27c6eeb4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV83LTQtMS0xLTA_f519846b-e791-4bd2-b1b1-0cc2a6d0f515">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTAtMS0xLTA_62c201ba-e7e2-4283-adc3-124971b3bff8">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTItMS0xLTA_236b7a76-6d2e-4ec3-82ad-288c88342596">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i282cc034e78b44beb71f281568135298_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGFibGU6MDJkZDQxNzA0N2QwNGY3MmIwNTE4YTQ4Y2YwZTUwYTEvdGFibGVyYW5nZTowMmRkNDE3MDQ3ZDA0ZjcyYjA1MThhNDhjZjBlNTBhMV84LTQtMS0xLTA_ba09fcc2-976c-4953-a2f4-aabc29b951ef">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5NmU1NDA1NmMyMDQwY2JhYWNiOTc2MGQ5ZGI0M2U0L3NlYzpiOTZlNTQwNTZjMjA0MGNiYWFjYjk3NjBkOWRiNDNlNF8xL2ZyYWc6YjcxOTdiMzdhNzU2NDdmYzk4ZGU1MjY5OWI0ZjAxZTgvdGV4dHJlZ2lvbjpiNzE5N2IzN2E3NTY0N2ZjOThkZTUyNjk5YjRmMDFlOF8xMjA4_0d0fd69c-3b89-49d7-8abc-62c1e8cbd926">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140687270558504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !(VFU('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  2-IM2C,2QS.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M:L,P$$5_I6AOCU^D13C>M&250J&!ENZ$-$E$K ?2%#M_7UM-'$K[ 5UJYNK,
M&9A6>BY=P)?@/ ;2&.]&T]O(I5^S(Y'G %$>T8B83PD[-?<N&$'3,QS "WD2
M!X2J*%9@D(02)& &9GXALJY5DLN @ERXX)5<\/XS] FF)&"/!BU%*/,26#=/
M].>Q;^$&F&&$P<3O JJ%F*I_8E,'V"4Y1KVDAF'(ASKEIAU*>'_>OJ9U,VTC
M"2MQ^A4UI[/'-;M.?JL?GW8;UE5%569%DU7WNV+%FP=>-Q^SZP^_F[!Q2N_U
M/S:^"G8M_+J+[@M02P,$%     @ $C:;4IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MD79H!1UL/+0X'@4#2\'@8!1T*.V="<N_X+7\<PB8!@2M6 (&AR*@0\C5@):
M@8N $0Y?I#V"E"T!@^,1,+ $# Y&0(?2OID@EH#DM01T")@&!*U8 I)#$= A
MY&A 8@E(8 +B,_]EV@/H1IE8 I+C$9!L/)<]& $=2GMGPA*0O): #@'=@+ 5
M2T!R* (ZA%P-: E(8 )Z/\_[ 'K&2RP!R?$(2"P!R<$(Z%#:-Q.A)6#X6@(Z
M!$P#@E8L <-#$= AY&C T!(PA D8G74Z+[(.P3ZT  R/!\#0 C \&  =2OLF
M8N/O4Z_EGT/ M!]HQ?(O/!3_'$*N]K/\"UTKP,[+.S]R#BE;_H7'XU]H^1<>
MC'\.I7TS$5G^1:_EGT- -R Y[T%>+ "C0P'0(;2M ]L;KQ:8US2^4/,HN40I
MFVH=[ZRCYYI<O?FPVE&BJ-XVN!=*B:S:G#.:,&D.T+]/A:[(>L>\P%"_?W+U
M'U!+ P04    "  2-IM2GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=
M5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=
MA['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6
M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?
MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C
M$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M
M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#
ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\
M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!
MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,
MD_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?
M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>
M\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O
M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R
M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N
MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@/
M/GL?)=-[*CG_5U/\!%!+ P04    "  2-IM2EXJ[',     3 @  "P   %]R
M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:
MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$
MVV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_
M,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH
M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( !(VFU(9117U-P$  "<"
M   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-
MB??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!
MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$
M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V
M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= 9.
MMO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977DHHM)]W1ZTSO'R:/
M6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ $C:;4B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ $C:;4@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  2-IM2C,2QS.\    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( !(VFU(9117U-P$  "<"   /
M  "  =81  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  2-IM2)!Z;HJT
M  #X 0  &@              @ $Z$P  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  2-IM299!YDAD!  #/ P  $P
M@ $?%   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !I%0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>9</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>8</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20210427.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20210427.htm">lly-20210427.htm</File>
    <File>lly-20210427.xsd</File>
    <File>lly-20210427_cal.xml</File>
    <File>lly-20210427_def.xml</File>
    <File>lly-20210427_lab.xml</File>
    <File>lly-20210427_pre.xml</File>
    <File>q121lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20210427.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 9,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20210427_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20210427_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20210427.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20210427_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20210427_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20210427.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 35,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 7,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20210427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210427.htm",
      "contextRef": "ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210427.htm",
      "contextRef": "ie3ebe8eea03c4af6837aa7fb80d1f2b4_D20210427-20210427",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 8,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20210427",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000059478-21-000117-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-21-000117-xbrl.zip
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M^1&;5)B"F)ARP:V PR#K*&SS("2A%=JVXN(#-2DI6]2<[Z?61VQ4Z2O3#JT
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MW8\X!O%V# +K?B)'\%\G[\6;_P=02P,$%     @ $C:;4KB<3^>I P  JQ
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M7VQA8BYX;6S-76V/V[C5_9Y?H<ZB10N$&5*D2#'/)L5T=K=(FTV"319;=/'
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MGQ=1T:O<W&X66O$H(B$&B!IBI2PPD%$4@3B)C$$1C3 BKE)N&VANDG[<!W8
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MQ,H*0'9U.,+,$N"F30))T7EOA<G"JA& N&-T& V[TV)]NJ);DAY>7\937Y[
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M:':,01\A]H'=,R]F!*@DFC$R05P@_U6XX$_D<7,/_5DA<XC9)PL6X$&VB!,
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M?B%=V[\;]CMU6NRCTU9>;0'>)C@ 2@!KVLAB,JU I5(3RVA4*2S%\D5]N4,
MP87/$TAN^&3@JQ^B[8R2^^'?CH$G .BCV%?K@8G%E\??HBVAG&IA"UVQ##:
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M3MKT+[>RFD9DR[;2D1\L-?_9B_^@.QO P80LE,Z;>PZJK\R^2%TZPG$E_$>
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M6:A )O!9-..V=*B(C#$NX^HV%O;W&$P 2ZU,&UK[*7HR)FCLJ\!)AP< 73\
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M7VZ''0F!9!?5=@$FB=\Y6%=>].IZ5&#MGA:U[/_&'.^-W_[VX4_?=(8W;RX
MEZS^1>%2S9@1<AP1XL0#6? ;;*DHB.U(^KO1H/)%E& (VB!:@/8,Z]2$*W;3
M$9'K":5/"7Z9(XU?3P;=HHZ8[(NHU\8]O!KS@V6*4A>!3NV!1J<G@^Y[8%98
M_B\DHH+Z/4M\7>@E!-D7+?%V#E@7)F->!#Y=&5:OBO'4'(PJ5Z;.;8@4&;")
MB_,@ [8!1MBJM_H<"%=?V)@]8:&:PWU,U,*&W#FKO59L>/@83^H*+AS/QRS
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MA6&< $_-3,)XL7"7BLUL<C&"AR28GR![4'MB%%:R)QA*(&Z#9,*%P H!DP+
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M,SP^9H$!-CP^7+O&:%!-<2J6K(D<\'STU>F1>F25D<7M9'I/T_BF26[!3[.
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M6M@8TTT:\5%GSCT>1H%(SGK6@J WZ!MM+0B.!\_NZ.Q&58T%@98#]1CYS.3
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M>2TR,#(Q,#0R-RYX<V102P$"% ,4    "  2-IM2I4%5Y8(!  #+ @  %
M            @ %&(0  ;&QY+3(P,C$P-#(W7V-A;"YX;6Q02P$"% ,4
M"  2-IM2@1W5X:H)   P2   %               @ 'Z(@  ;&QY+3(P,C$P
M-#(W7V1E9BYX;6Q02P$"% ,4    "  2-IM2X1JYT<@/   .EP  %
M        @ '6+   ;&QY+3(P,C$P-#(W7VQA8BYX;6Q02P$"% ,4    "  2
M-IM2\>VY@$4)   .3   %               @ '0/   ;&QY+3(P,C$P-#(W
M7W!R92YX;6Q02P$"% ,4    "  2-IM2RN&F7O%=  "\!@4 '@
M    @ %'1@  <3$R,6QI;&QY<V%L97-A;F1E87)N:6YG<W N:'1M4$L%!@
0   '  < T $  '2D      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
